Captor Therapeutics SA
WSE:CTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Captor Therapeutics SA
Total Current Assets
Captor Therapeutics SA
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Captor Therapeutics SA
WSE:CTX
|
Total Current Assets
zł78.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
M
|
Marvipol Development SA
WSE:MVP
|
Total Current Assets
zł1.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
M
|
MLP Group SA
WSE:MLG
|
Total Current Assets
zł251.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-8%
|
|
|
L
|
Lokum Deweloper SA
WSE:LKD
|
Total Current Assets
zł788.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
C
|
CFI Holding SA
WSE:CFI
|
Total Current Assets
zł380.8m
|
CAGR 3-Years
45%
|
CAGR 5-Years
21%
|
CAGR 10-Years
21%
|
|
|
D
|
Develia SA
WSE:DVL
|
Total Current Assets
zł4.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
15%
|
|
Captor Therapeutics SA
Glance View
Captor Therapeutics SA engages in the development of protein degradation drugs for cancer and autoimmune diseases. The company is headquartered in Wroclaw, Woj. Dolnoslaskie and currently employs 98 full-time employees. The company went IPO on 2021-04-19. The firm works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The firm covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
See Also
What is Captor Therapeutics SA's Total Current Assets?
Total Current Assets
78.1m
PLN
Based on the financial report for Dec 31, 2024, Captor Therapeutics SA's Total Current Assets amounts to 78.1m PLN.
What is Captor Therapeutics SA's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
40%
Over the last year, the Total Current Assets growth was -12%. The average annual Total Current Assets growth rates for Captor Therapeutics SA have been -16% over the past three years , 40% over the past five years .
